Dioseve Raises Over ¥1 Billion in Series A Extension Round, Attracting Overseas Investors and Major Pharmaceutical Companies, and Selected for NEDO DTSU
Key facts
- Dioseve Raises Over ¥1 Billion in Series A Extension Round, Attracting Overseas Investors and Major Pharmaceutical Companies, and Selected for NEDO DTSU
- Dioseve Inc. has successfully closed its Series A extension round, raising over ¥1 billion, bringing its total funding to ¥2.5 billion. The round saw participation from overseas investors and major pharmaceutical companies, accelerating the commercialization of its iPS cell-derived oocyte in vitro maturation product, 'ReproNest'. The company was also selected for the NEDO DTSU program.
- Source: PR Times
- Date: June 12, 2026
Direct answer
Dioseve Inc. has successfully closed its Series A extension round, raising over ¥1 billion, bringing its total funding to ¥2.5 billion. The round saw participation from overseas investors and major pharmaceutical companies, accelerating the commercialization of its iPS cell-derived oocyte in vitro maturation product, 'ReproNest'. The company was also selected for the NEDO DTSU program.
- Citation
- Dioseve Raises Over ¥1 Billion in Series A Extension Round, Attracting Overseas Investors and Major Pharmaceutical Companies, and Selected for NEDO DTSU (June 12, 2026), PR Times
- Source
- PR Times
- Date
- June 12, 2026
Dioseve Inc. has successfully closed its Series A extension round, raising over ¥1 billion, bringing its total funding to ¥2.5 billion. The round saw participation from overseas investors and major pharmaceutical companies, accelerating the commercialization of its iPS cell-derived oocyte in vitro maturation product, 'ReproNest'. The company was also selected for the NEDO DTSU program.
📋 Article Processing Timeline
- 📰 Published: June 12, 2026 at 12:00
- 🔍 Collected: June 12, 2026 at 12:29 (29 min after Published)
- 🤖 AI Analyzed: June 12, 2026 at 16:52 (4h 22m after Collected)
Dioseve Inc. (Headquarters: Tokyo, CEO: Kazuma Kishida, hereinafter "Dioseve") announced today that it has completed a Series A extension round of funding, raising over ¥1 billion through a third-party allotment of shares. The round was led by existing shareholder Archetype Ventures, with participation from DG Daiwa Ventures, Mirai-do (Asuka Innovation Fund), and new investors D4V, Shionogi & Co., Ltd., and Pangaea Ventures. This brings the total equity funding raised to ¥2.5 billion.
Through investments from overseas investors and pharmaceutical companies in this round, Dioseve will further promote domestic and international business development towards the practical application of "ReproNest," its product for in vitro maturation of oocytes using its proprietary iPS cell differentiation induction technology.
Furthermore, Dioseve has been selected for the 8th NEDO Deep Tech Startup Support Program (DTSU). Including this selection, the total amount raised reaches ¥2.9 billion.
In conjunction with this, we are pleased to announce that Professor Katsuhiko Hayashi, a leading expert in the field of reproductive medicine (Graduate School of Medicine, Osaka University), has been appointed as a technical advisor to our company.
Background of Funding
Dioseve is a startup in the field of reproductive medicine that is engaged in the research and development of "ReproNest" (development code: DIOS-101), a co-culture product that supports the in vitro maturation of immature oocytes using ovarian somatic cell-like cells derived from iPS cells, and its related technologies.
ReproNest is not a cell therapy product administered directly to the patient's body, but rather a co-culture product candidate aimed at supporting the oocyte maturation environment in vitro during the in vitro fertilization (IVF) process. By leveraging our unique iPS cell differentiation induction technology, we are advancing research and development to improve the efficiency of in vitro maturation (IVM) of immature oocytes.
In preclinical studies to date, ReproNest has yielded results indicating its potential to support the maturation of immature oocytes compared to conventional IVM culture conditions. The company is currently proceeding with verification of manufacturing processes, quality evaluation, and reproducibility towards the commercialization of the product.
Current IVF treatments generally involve approximately 10 days of hormone stimulation, frequent clinic visits, physical and mental burdens associated with self-injections, and medication costs, all of which are borne by the patient. ReproNest aims to reduce the burden on patients by combining short-term stimulation with in vitro oocyte maturation culture, thereby reducing the burden associated with medication administration and clinic visits in IVF.
In the future, we are also considering potential applications for a variety of needs, including fertility preservation including oocyte cryopreservation, patients at high risk of ovarian hyperstimulation syndrome (OHSS), and patients requiring rapid fertility preservation before cancer treatment.
With the selection for the NEDO Deep Tech Startup Support Program (DTSU), the total amount raised has reached ¥2.9 billion. This will enable Dioseve to further promote verification for the commercialization of ReproNest, establish manufacturing and quality control systems, and advance regulatory compliance and business development both domestically and internationally.
Appointment of Professor Katsuhiko Hayashi as Technical Advisor
We are pleased to announce that Professor Katsuhiko Hayashi, a world-renowned researcher in the fields of reproductive medicine and developmental biology (Graduate School of Medicine, Osaka University), has been appointed as a technical advisor to Dioseve.
Professor Hayashi has published numerous pioneering research findings in the field of germ cell research using iPS cells and is one of the researchers who has led the fields of reproductive medicine and developmental biology. He was selected for "Nature's 10" by the British scientific journal Nature in 2023 and for "TIME100" by TIME magazine in 2024.
With Professor Hayashi's participation, Dioseve will further strengthen its research foundation and accelerate research and development towards the social implementation of new options in assisted reproductive technology.
Company Profile
Company Name: Dioseve Inc.
Location: Shinkiba, Koto-ku, Tokyo
Representative: Kazuma Kishida, CEO
Business Description: Research and development of assisted reproductive technology-related products utilizing iPS cell differentiation induction technology, and establishment of manufacturing systems. URL: https://dioseve.com/
This press release contains information as of the date of announcement.
Through investments from overseas investors and pharmaceutical companies in this round, Dioseve will further promote domestic and international business development towards the practical application of "ReproNest," its product for in vitro maturation of oocytes using its proprietary iPS cell differentiation induction technology.
Furthermore, Dioseve has been selected for the 8th NEDO Deep Tech Startup Support Program (DTSU). Including this selection, the total amount raised reaches ¥2.9 billion.
In conjunction with this, we are pleased to announce that Professor Katsuhiko Hayashi, a leading expert in the field of reproductive medicine (Graduate School of Medicine, Osaka University), has been appointed as a technical advisor to our company.
Background of Funding
Dioseve is a startup in the field of reproductive medicine that is engaged in the research and development of "ReproNest" (development code: DIOS-101), a co-culture product that supports the in vitro maturation of immature oocytes using ovarian somatic cell-like cells derived from iPS cells, and its related technologies.
ReproNest is not a cell therapy product administered directly to the patient's body, but rather a co-culture product candidate aimed at supporting the oocyte maturation environment in vitro during the in vitro fertilization (IVF) process. By leveraging our unique iPS cell differentiation induction technology, we are advancing research and development to improve the efficiency of in vitro maturation (IVM) of immature oocytes.
In preclinical studies to date, ReproNest has yielded results indicating its potential to support the maturation of immature oocytes compared to conventional IVM culture conditions. The company is currently proceeding with verification of manufacturing processes, quality evaluation, and reproducibility towards the commercialization of the product.
Current IVF treatments generally involve approximately 10 days of hormone stimulation, frequent clinic visits, physical and mental burdens associated with self-injections, and medication costs, all of which are borne by the patient. ReproNest aims to reduce the burden on patients by combining short-term stimulation with in vitro oocyte maturation culture, thereby reducing the burden associated with medication administration and clinic visits in IVF.
In the future, we are also considering potential applications for a variety of needs, including fertility preservation including oocyte cryopreservation, patients at high risk of ovarian hyperstimulation syndrome (OHSS), and patients requiring rapid fertility preservation before cancer treatment.
With the selection for the NEDO Deep Tech Startup Support Program (DTSU), the total amount raised has reached ¥2.9 billion. This will enable Dioseve to further promote verification for the commercialization of ReproNest, establish manufacturing and quality control systems, and advance regulatory compliance and business development both domestically and internationally.
Appointment of Professor Katsuhiko Hayashi as Technical Advisor
We are pleased to announce that Professor Katsuhiko Hayashi, a world-renowned researcher in the fields of reproductive medicine and developmental biology (Graduate School of Medicine, Osaka University), has been appointed as a technical advisor to Dioseve.
Professor Hayashi has published numerous pioneering research findings in the field of germ cell research using iPS cells and is one of the researchers who has led the fields of reproductive medicine and developmental biology. He was selected for "Nature's 10" by the British scientific journal Nature in 2023 and for "TIME100" by TIME magazine in 2024.
With Professor Hayashi's participation, Dioseve will further strengthen its research foundation and accelerate research and development towards the social implementation of new options in assisted reproductive technology.
Company Profile
Company Name: Dioseve Inc.
Location: Shinkiba, Koto-ku, Tokyo
Representative: Kazuma Kishida, CEO
Business Description: Research and development of assisted reproductive technology-related products utilizing iPS cell differentiation induction technology, and establishment of manufacturing systems. URL: https://dioseve.com/
This press release contains information as of the date of announcement.
FAQ
What problem does Dioseve's 'ReproNest' aim to solve?
It aims to reduce patient burdens such as physical and mental stress from hormone stimulation, frequent clinic visits, self-injections, and medication costs in conventional IVF.
How is iPS cell technology applied to reproductive medicine?
Dioseve utilizes iPS cell differentiation induction technology to develop products that support in vitro maturation of immature oocytes, contributing to improved efficiency and reduced patient burden in reproductive medicine.
How will this funding impact Dioseve's business?
The funds raised will accelerate the verification for commercialization of the product 'ReproNest,' the establishment of manufacturing and quality control systems, and domestic and international business development.